Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?

The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encoura...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Castelnuovo, Augusto, Costanzo, Simona, Gialluisi, Alessandro, Iacoviello, Licia, de Gaetano, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547940/
https://www.ncbi.nlm.nih.gov/pubmed/34750033
http://dx.doi.org/10.1016/j.ejim.2021.10.026
Descripción
Sumario:The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encouraged. However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials.

Ejemplares similares